ArticleClinical, cosmetic and investigational dermatology2024
Upadacitinib for Alopecia Areata in Different Backgrounds: A Case Series.
Article in Clinical, cosmetic and investigational dermatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 8 citations in OpenAlex.
- Upadacitinib for the Management of Alopecia Totalis and Subtotalis in Pediatric Patients: A Case Series.Reports (MDPI) · 2026Article
- JAK-Inhibitors Beyond the Label: Emerging Applications in Dermatology.Medicina (Kaunas, Lithuania) · 2026Review
- JAK Inhibitors for Alopecia Areata: Approved Therapies, Efficacy, and Unanswered Questions.Drug design, development and therapy · 2026Review
- Alopecia Areata - Effects of Treatment with Upadacitinib - Two Case Reports.Clinical, cosmetic and investigational dermatology · 2026Article
- Upadacitinib for Alopecia: Current Evidence and Clinical Insights.Skin appendage disorders · 2025Review
- Significant efficacy of tofacitinib from China in the treatment of alopecia areata: a case report.Frontiers in immunology · 2025Article
- Drug-Induced Alopecia Areata From Upadacitinib.Cureus · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alopecia Areata is a hair disorder influenced by factors such as genetics, immune system, and environmental triggers. The pathogenesis of this condition is still unclear, leading to unsatisfactory current treatments and causing a large number of patients to suffer from it. Janus kinase inhibitors are a new class of drugs that have emerged in recent years and are expected to be promising therapeutic tools for alopecia areata. We report five patients with varying backgrounds and severity of alopecia areata. All of them had received conventional therapy without success. Five patients took Upadacitinib at a dose of 15 mg once daily, and all of them achieved satisfactory efficacy. No adverse events were observed during the treatment of 5 patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.